Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...

The European Medicines Authority’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for a new drug to treat hereditary angioedema (HAE).

Hereditary Angioedema Attack Rates in Children 2-12 with Oral Prophylactic Berotralstat Over One Year; ePoster #R089; Friday, November 7, 2:50–3:05 p.m. ET; Monitor #15, West Exhibit Hall Psychosocial ...

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE ...

Like angioedema in general, hereditary angioedema (HAE) is characterized by subcutaneous or submucosal edema that is nonpruritic — ie, does not itch — and nonpitting — ie, does not leave an ...

ORLANDO -- An orally disintegrating tablet form of sebetralstat (Ekterly) for young children with hereditary angioedema (HAE) showed similar results as the non-disintegrating tablet used in adults, a ...

– ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P – – ORLADEYO oral granules are currently under review ...

KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...

Rare diseases pose a substantial burden to patients and the healthcare system, comparable to those of cancer and heart failure. [i] Thankfully, advances in diagnosis and healthcare delivery can help ...